Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
== Types == There are three primary and two secondary types of dialysis: hemodialysis (primary), peritoneal dialysis (primary), hemofiltration (primary), hemodiafiltration (secondary) and intestinal dialysis (secondary).
The Hukbong Bayan Laban sa Hapon (lit. 'People's Army Against the Japanese'), better known by the abbreviation Hukbalahap, was a Filipino communist guerrilla movement formed by the farmers of Central Luzon. They were originally formed to fight the Japanese, but extended their fight into a rebellion against the Philippine government, known as the Hukbalahap rebellion in 1946. It was eventually put down through a series of reforms and military victories by Defense Secretary, and later President, Ramon Magsaysay. Constituted in March 1942, the Hukbalahap was to be part of a broad united front resistance to the Japanese occupation of the Philippines. This original intent is reflected in its name. By 1950, the Communist Party of the Philippines (PKP) had resolved to reconstitute the organization as the armed wing of a revolutionary party, prompting a change in the official name to Hukbong Mapagpalaya ng Bayan, likely in emulation of the Chinese People's Liberation Army. Notwithstanding this name change, the HMB continued to be popularly known as the Hukbalahap, and the English-speaking press continued to refer to it and its members, interchangeably, as the Huks (Singular: Huk) during the whole period between 1945 and 1952. A monument dedicated to the Huks in Cabiao, Nueva Ecija, was constructed to honor their actions during World War II. On October 14, 2023, the Luis M.
Tellurocysteine (in some publications referred to as Te-Cys) is an amino acid with the formula HTeCH2CH(NH2)CO2H. It is the heavy analogue of serine, cysteine, and selenocysteine. Tellurol (RTeH) is a rare and fragile functional group, especially alkyl derivatives. The C-Te bond (200 kJ/mol) is weak compared to 234 kJ/mol for the C-Se bond. These factors combine to make tellurocysteine very labile. Even selenocysteine occurs only rarely in nature. Instead of tellurocysteine, tellurocystine is generally isolated instead. Tellurocystine has the formula (TeCH2CH(NH2)CO2H)2, with a central Te-Te bond.
Four entities are given authority under the drug conventions: the Commission on Narcotic Drugs (CND), the UN Office on Drugs and Crime (UNODC), the International Narcotics Control Board (INCB), and the World Health Organization (WHO). The 53-member CND, a subsidiary organ of the Economic and Social Council (ECOSOC), is the UN's main drug policy body, responsible for the drug classification schedules and policy guidance. Members are elected by ECOSOC, one of the six UN main organs. The CND also is the governing body of the UNODC, which advises governments on implementation of the conventions and produces an annual World Drug Report. UNODC's focus is mainly on security and law enforcement, rather than public health. The INCB is an independent treaty body, mandated by the Single Convention, that monitors implementation of the conventions, oversees the legal drug supply, and maintains discussions with countries regarding compliance issues. Central to its function is an annual set of reports, submitted to ECOSOC through the CND, that overlook the global drug situation. The reporting identifies and predicts problem trends and suggests corrective actions. Technical reports list estimated national requirements, and production, manufacture, trade and consumption data, for controlled drugs for medical and scientific use, gathered from individual countries. Trends in trafficking in precursors and essential chemicals for illicit drug manufacture, and evaluation of government measures taken to prevent that traffic, are also reported.
Sources: en.wikipedia.org
== Synthesis == Etonitazene and related nitazene opioids were discovered in the late 1950s, by a team of Swiss researchers working at the pharmaceutical firm CIBA (now Novartis). One of the first compounds investigated by the Swiss team was 1-(β-diethylaminoethyl)-2-benzylbenzimidazole, which was found to possess 10% of the analgesic activity of morphine when tested in rodent bioassays. This finding encouraged the group to begin a comprehensive systematic study of 2-benzylbenzimidazoles and to establish the structure-activity relationship of this new family of analgesics. Two general synthetic methods were developed for the preparation of these compounds. The first method involved the condensation of o-phenylenediamine with para-ethoxy-phenylacetonitrile to form a 2-benzylbenzimidazole. The benzimidazole is then alkylated with the desired 1-chloro-2-dialkylaminoethane, forming the final product. This particular procedure was most useful for the preparation of benzimidazoles that lacked substituents on the benzene rings. A diagram of this method is displayed below.
Efficacy was evaluated in KEYNOTE-A18 (NCT04221945), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 1060 participants with cervical cancer who had not previously received definitive surgery, radiation, or systemic therapy. The trial included 596 participants with FIGO 2014 Stage III-IVA disease and 462 participants with FIGO 2014 Stage IB2-IIB, node-positive disease. In June 2024, the US FDA approved pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma. Efficacy was evaluated in KEYNOTE-868/NRG-GY018 (NCT03914612), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 810 participants with advanced or recurrent endometrial carcinoma. The trial included two separate cohorts based on mismatch repair status: 222 participants in the mismatch repair deficient cohort, and 588 participants in the mismatch repair proficient cohort. Efficacy was evaluated in KEYNOTE-905/EV-303 (NCT03924895), an open-label, randomized, multi-center, active-controlled trial in 344 participants with previously untreated muscle invasive bladder cancer who were candidates for radical cystectomy with pelvic lymph node dissection but were ineligible for or declined cisplatin-based chemotherapy.
Now burdened by the guilt of killing her friends and countless cityfolk, Angela refuses to leave the Library and continues her aimless destruction for years before letting a nameless follower end her life. To avoid this ending, the realizations needed to be completed are on the floors of History, Technological Sciences, Literature, and Art. If all of Roland's Floor realizations have not been completed, Roland will swiftly behead Angela before returning to the City, his life spiraling into alcoholism, drug abuse and wanton slaughter before eventually dying meaninglessly in a gutter. The player must complete the realizations of the floors of Natural Sciences, Language, Social Sciences, Philosophy, and Religion or they will be locked to this ending. If all Floor realizations have been completed and Angela and Roland choose to forgive each other, Angela will release the culminated Light and resurrect all lives the Library has taken, kickstarting the Kether floor realization against Carmen, founder of Lobotomy Corporation's Seed of Light and actual mastermind behind the Distortion phenomenon. Meanwhile, Roland and the Library fight back the returned Reverberation Ensemble, now empowered by the Light, for 7 days; Roland saves Angela from dissipating inside the Light and kills Argalia for good. The Library soon receives the arrival of Zena, Luda and Baral, agents sent by Head to quell dissidents against the government and those who break important rules of the City.
Sources: en.wikipedia.org
The canonical example of a ligand-binding protein is haemoglobin, which transports oxygen from the lungs to other organs and tissues in all vertebrates and has close homologs in every biological kingdom. Lectins are sugar-binding proteins which are highly specific for their sugar moieties. Lectins typically play a role in biological recognition phenomena involving cells and proteins. Receptors are highly specific binding proteins, and many hormones act by binding specifically to their receptors. Transmembrane proteins can serve as ligand transport proteins that alter the permeability of the cell membrane to small molecules and ions. The membrane alone has a hydrophobic core through which polar or charged molecules cannot diffuse. Membrane proteins contain internal channels that allow such molecules to enter and exit the cell. Many ion channel proteins are specialized to select for only a particular ion; for example, potassium and sodium channels often discriminate for only one of the two ions.
Bethlem myopathy is predominantly an autosomal dominant myopathy, classified as a congenital form of limb-girdle muscular dystrophy. There are two types of Bethlem myopathy, based on which type of collagen is affected. Bethlem myopathy 1 (BTHLM1) is caused by a mutation in one of the three genes coding for type VI collagen. These include COL6A1, COL6A2, and COL6A3. It is typically autosomal dominant, though uncommonly can be autosomal recessive. Bethlem myopathy 2 (BTHLM2), formerly known as myopathic-type Ehlers–Danlos syndrome, is caused by a mutation on the COL12A1 gene coding for type XII collagen. It is autosomal dominant. In 2017, an international workshop proposed a redefined criteria and naming system for limb-girdle muscular dystrophies. Bethlem myopathy 1 (collagen VI) was included into the proposed list and renamed LGMDD5 for autosomal dominant mutations and LGMDR22 for recessive mutations. Bethlem myopathy 2 (collagen XII) was not addressed. Gowers's sign, toe walking, multiple contractures of the joints (especially the fingers: 'Bethlem sign'), skin abnormalities, and muscle weakness (proximal more than distal) are typical signs and symptoms of the disease. Initially, in early childhood, there may also be joint laxity. There is no cardiac involvement in either Bethlem myopathy 1 or 2, which helps to differentiate it from Emery–Dreifuss muscular dystrophy. Currently there is no cure for the disease and symptomatic treatment is used to relieve symptoms and improve quality of life.
Indium is created by the long-lasting (up to thousands of years) s-process (slow neutron capture) in low-to-medium-mass stars (range in mass between 0.6 and 10 solar masses). When a silver-109 atom captures a neutron, it transmutes into silver-110, which then undergoes beta decay to become cadmium-110. Capturing further neutrons, it becomes cadmium-115, which decays to indium-115 by another beta decay. This explains why the radioactive isotope is more abundant than the stable one. The stable indium isotope, indium-113, is one of the p-nuclei, the origin of which is not fully understood; although indium-113 is known to be made directly in the s- and r-processes (rapid neutron capture), and also as the daughter of very long-lived cadmium-113, which has a half-life of about eight quadrillion years, this cannot account for all indium-113. Indium is the 68th most abundant element in Earth's crust at approximately 50 ppb. This is similar to the crustal abundance of silver, bismuth and mercury. It very rarely forms its own minerals, or occurs in elemental form. Fewer than 10 indium minerals such as roquesite (CuInS2) are known, and none occur at sufficient concentrations for economic extraction. Instead, indium is usually a trace constituent of more common ore minerals, such as sphalerite and chalcopyrite. From these, it can be extracted as a by-product during smelting. While the enrichment of indium in these deposits is high relative to its crustal abundance, it is insufficient, at current prices, to support extraction of indium as the main product.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.